UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cellular uptake of dietary flavonoid quercetin 4'-beta-glucoside by sodium-dependent glucose transporter SGLT1

The Journal of pharmacology and experimental therapeutics, 2000-09, Vol.294 (3), p.837

2000

Volltextzugriff (PDF)

Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2

The Journal of pharmacology and experimental therapeutics, 2000-09, Vol.294 (3), p.830

2000

Volltextzugriff (PDF)

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F

Blood cancer journal (New York), 2013-04, Vol.3 (4), p.e109-e109

2013

Volltextzugriff (PDF)

Transport of Quercetin and Its Glucosides across Human Intestinal Epithelial Caco-2 Cells

Biochemical pharmacology, 1998-05, Vol.55 (10), p.1721-1727

1998

Volltextzugriff (PDF)

P639: OUTCOMES FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA PREVIOUSLY TREATED WITH A COVALENT BTK AND BCL2 INHIBITOR IN THE UNITED STATES: A REAL‐WORLD DATABASE STUDY

HemaSphere, 2022-06, Vol.6, p.537-538

2022

Volltextzugriff (PDF)

P653: OUTCOMES FOLLOWING TREATMENT WITH A COVALENT BTK AND BCL2 INHIBITOR AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): A REAL‐WORLD STUDY OF A LARGE U.S. DATABASE

HemaSphere, 2022-06, Vol.6, p.551-552

2022

Volltextzugriff (PDF)

The Influence of Plasma Binding on Absorption/Exsorption in the Caco-2 Model of Human Intestinal Absorption

Journal of pharmacy and pharmacology, 1999-09, Vol.51 (9), p.1037-1040

1999

Volltextzugriff (PDF)

Cisplatin and gemcitabine plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase 2 trial

Annals of oncology, 2016-10, Vol.27, p.vi240-vi240

2016

Volltextzugriff (PDF)

RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results

Annals of oncology, 2018-10, Vol.29, p.viii304-viii305

2018

Volltextzugriff (PDF)

865PDRANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Transport of genistein-7-glucoside by human intestinal CACO-2 cells: potential role for MRP2

Research communications in molecular pathology and pharmacology, 1999-01, Vol.103 (1), p.45

1999

Volltextzugriff (PDF)

Pharmacogenomic Discovery Approaches: Will the Real Genes Please Stand Up?

Journal of clinical oncology, 2005-10, Vol.23 (29), p.7342-7349

2005

Volltextzugriff (PDF)

A phase II study of intravenous azacitidine alone in patients with myelodysplastic syndromes: NCT0038495

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.7097-7097

2008

Volltextzugriff (PDF)

Small inhibitory RNA -– a tool for credentialing candidate genes

Pharmacogenomics, 2005-04, Vol.6 (3), p.281-292

2005

Volltextzugriff (PDF)

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

Oncotarget, 2018-03, Vol.9 (17), p.13796-13806

2018

Volltextzugriff (PDF)

Coupled behavior of shape memory alloy-based morphing spacecraft radiators: experimental assessment and analysis

Smart materials and structures, 2018-06, Vol.27 (6), p.65006

2018

Volltextzugriff (PDF)

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms

Leukemia research, 2018-08, Vol.71, p.82-88

2018

Volltextzugriff (PDF)

Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study

Clinical lymphoma, myeloma and leukemia, 2023-01, Vol.23 (1), p.57-67

2023

Volltextzugriff (PDF)

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Molecular cancer therapeutics, 2019-12, Vol.18 (12), p.2207-2219

2019

Volltextzugriff (PDF)

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

Investigational new drugs, 2013-08, Vol.31 (4), p.833-844

2013

Volltextzugriff (PDF)

Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study

Current medical research and opinion, 2021-10, Vol.37 (10), p.1769-1778

2021

Volltextzugriff (PDF)

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

Investigational new drugs, 2018-08, Vol.36 (4), p.536-544

2018

Volltextzugriff (PDF)

Discovery of 1‑(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3‑d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells

Journal of medicinal chemistry, 2015-05, Vol.58 (10), p.4165-4179

2015

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(51)

Publikationsform

Sprache

Englisch
(59)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(24)
Humans
(19)
Pharmacology & Pharmacy
(10)
Animals
(9)
Oncology
(9)
Biological And Medical Sciences
(6)
Male
(6)
Adult
(5)
Female
(5)
Medical Sciences
(5)
Aged
(4)
Antineoplastic Agents - Pharmacology
(4)
Biological Transport
(4)
Cell Line, Tumor
(4)
Hematology
(4)
Ly2801653
(4)
Middle Aged
(4)
Mutation
(4)
Protein Kinase Inhibitors - Pharmacology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cellular uptake of dietary flavonoid quercetin 4'-beta-glucoside by sodium-dependent glucose transporter SGLT1

Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F

Transport of Quercetin and Its Glucosides across Human Intestinal Epithelial Caco-2 Cells

P639: OUTCOMES FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA PREVIOUSLY TREATED WITH A COVALENT BTK AND BCL2 INHIBITOR IN THE UNITED STATES: A REAL‐WORLD DATABASE STUDY

P653: OUTCOMES FOLLOWING TREATMENT WITH A COVALENT BTK AND BCL2 INHIBITOR AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): A REAL‐WORLD STUDY OF A LARGE U.S. DATABASE

The Influence of Plasma Binding on Absorption/Exsorption in the Caco-2 Model of Human Intestinal Absorption

Cisplatin and gemcitabine plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase 2 trial

RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results

865PDRANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results

Transport of genistein-7-glucoside by human intestinal CACO-2 cells: potential role for MRP2

Pharmacogenomic Discovery Approaches: Will the Real Genes Please Stand Up?

A phase II study of intravenous azacitidine alone in patients with myelodysplastic syndromes: NCT0038495

Small inhibitory RNA -– a tool for credentialing candidate genes

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

Coupled behavior of shape memory alloy-based morphing spacecraft radiators: experimental assessment and analysis

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms

Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

Discovery of 1‑(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3‑d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Suchergebnisse filtern